A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
Phase 2
Withdrawn
- Conditions
- Allergic Conjunctivitis
- Registration Number
- NCT00375596
- Lead Sponsor
- Bausch & Lomb Incorporated
- Brief Summary
This study will evaluate the safety and efficacy of a new allergy medication
- Detailed Description
Study withdrawn prior to determining study details
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Be at least 6 years of age, of any race, or either gender.
- Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
- Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
- Positive bilateral CAC reaction at Visit 1 & 2.
Exclusion Criteria
- Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
- Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
- Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety and efficacy of a new allergy medication 0 STUDY WITHDRAWN PRIOR TO OUTCOME DETERMINATION
- Secondary Outcome Measures
Name Time Method